Concept of a point of care test to detect new oral anticoagulants in urine samplesReportar como inadecuado




Concept of a point of care test to detect new oral anticoagulants in urine samples - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Thrombosis Journal

, 11:15

First Online: 01 August 2013Received: 04 April 2013Accepted: 16 July 2013

Abstract

New oral anticoagulants NOAC are approved for several indications for prophylaxis and treatment of venous thromboembolism and for prevention of embolism in atrial fibrillation at fixed daily doses without need of laboratory guided dose adjustment. Due to their low molecular weight of about 500 to 600 Dalton and their hydrophilicity free anticoagulant is excreted immediately through glomerular filtration into the urine. Impairment of renal function may increase the plasma concentration of the anticoagulants and lowered creatinine clearance is a declared contraindication. In contrast to the initial aim of development the anticoagulant effect is required to be determined in special clinical situations. Several specific and non-specific assays using plasma samples are currently undergoing standardization. As all NOACs are excreted into the urine, specific assays were developed for this matrix to determine them quantitatively of qualitatively. Urine samples can be easily and repetitively obtained avoiding problems and risks associated with blood sampling. The qualitative assay can be performed as a point of care test POC also by the patient by judging the different colours for the absence or presence of the drugs with the naked eye. The test is rapid results available within 15 min, sensitive, specific and accurate and does not require a purified NOAC as control. The tests may be a tool for clinicians who need to know for treatment decisions if a NOAC is on board or not. As the tests are specific for oral direct thrombin inhibitors and for oral direct factor Xa inhibitors, the indication does not interfere with other qualitative POC test in development using clotting systems. The test may be indicated for patients at acute hospitalization, before surgery or central nervous system puncture anaesthesia, if fibrinolytic therapy is indicated, acute deterioration of renal function, and for control of adherence to therapy.

KeywordsOral anticoagulant Dabigatran Rivaroxaban Apixaban Renal function Anticoagulation Urine Coagulation assay Monitoring Compliance Electronic supplementary materialThe online version of this article doi:10.1186-1477-9560-11-15 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Job Harenberg - Sandra Krämer - Shanshan Du - Christel Weiss - Roland Krämer

Fuente: https://link.springer.com/article/10.1186/1477-9560-11-15



DESCARGAR PDF




Documentos relacionados